Table 2. The descriptive characteristics and distribution of patients according to objective response of treatment.
| Patients’ characteristics | No. of total patients | OR | Failure | P |
|---|---|---|---|---|
| No. of patients | 15 | 11 (73.3%) | 4 (26.7%) | |
| Age (y/o) | ||||
| Range | 31-81 | |||
| Median | 56.0 | |||
| Mean | 59.5±13.7 | |||
| ≧70 | 5 | 4 | 1 | .680 |
| <70 | 10 | 7 | 3 | |
| Gender | ||||
| Male | 9 | 6 | 3 | .475 |
| Female | 6 | 5 | 1 | |
| Tumor Site | ||||
| R-colon | 4 | 3 | 1 | .930 |
| L-colon | 11 | 8 | 3 | |
| Liver Mets | ||||
| Y | 13 | 9 | 4 | .360 |
| N | 2 | 2 | 0 | |
| ECOG PS | ||||
| 2 | 12 | 11 | 1 | .001 |
| 3 | 3 | 0 | 3 | |
| WBC (/mm3) | ||||
| Range | 2300-37200 | |||
| Median | 5900.0 | |||
| Mean | 8306.0±8447.8 | |||
| >10000 | 3 | 1 | 2 | .080 |
| ≦10000 | 12 | 10 | 2 | |
| Hb (g/dl) | ||||
| Range | 6.9-13.8 | |||
| Median | 10.8 | |||
| Mean | 10.9±1.7 | |||
| ≧12 | 3 | 2 | 1 | .770 |
| <12 | 12 | 9 | 3 | |
| PLT (x103/mm3) | ||||
| Range | 73-449 | |||
| Median | 203.0 | |||
| Mean | 212.8±111.5 | |||
| ≧150 | 10 | 8 | 2 | .409 |
| <150 | 5 | 3 | 2 | |
| SAAG (g/dl)* | ||||
| Range | 0.48-1.96 | |||
| Median | 1.035 | |||
| Mean | 1.084±0.468 | |||
| ≧1.1 | 4 | 1 | 3 | .011 |
| <1.1 | 6 | 6 | 0 | |
| Dosage of ziv-aflibercept | ||||
| 50mg | 9 | 8 | 1 | .095 |
| 100mg | 6 | 3 | 3 | |
| Follow-up (weeks) | ||||
| Range | 0.0-55.0 | |||
| Median | 12.0 | |||
| Mean | 18.9±17.9 |
* Missing data in 5 patients.
Abbreviations: ECOG: Eastern Cooperative Oncology Group performance status; Hb: hemoglobin; L-colon: left side colon cancer; Mets: metastasis; N: no; No.: number; OR: objective response; P: probability value; PLT: platelet; R-colon: right side colon cancer; SAAG: serum ascites albumin gradient; WBC: white blood cell; Y: yes; y/o: years old.